Medifast's Trilivy Bet: Metabolic Health Pivot Meets a Shrinking Coach Base

Coach productivity surges 41% YoY, but revenue falls 27.6%; a cash-rich balance sheet and Catalyst cost cuts target Q4 profitability.

MED · Earnings Call · 2026-08-03

New Brand, New Leader, Old Challenge

Medifast's second-quarter earnings call marked the debut of CEO Nick Johnson, who wasted no time framing the company's future around a sweeping strategic overhaul. The centerpiece is new consumer brand Trilivy, which replaces OPTAVIA as the primary offer. “Trilivy is the first step in our 3.0 strategy, which is the biggest shift for Medifast since we launched OPTAVIA in 2017.” — Nicholas Johnson, Chief Executive Officer · 2026-08-03 The pivot is built on a metabolic health narrative—one that goes beyond weight loss to address body composition, lean mass preservation, and reversal of metabolic dysfunction. Johnson emphasized the science: “Our clinically proven plans activate targeted fat burn while preserving lean mass.” This repositioning aims to capture a market where 90% of U.S. adults are metabolically unhealthy. The shift comes amid a brutal fundamental backdrop. Revenue for Q2 2026 was $76.4 million, down 27.6% year-over-year, driven by a 48.7% decline in active earning coaches. Revenue has plunged from a peak of $416M in mid-2022 to $76M. Gross margin contracted to 69.9% from 72.6%, and the company posted a net loss of $3.1 million versus a $2.5 million profit a year earlier. Yet the balance sheet remains a fortress: $169.8 million in cash and investments, no debt, and working capital expected to exceed $145 million by year-end.

Coach Productivity: A Leading Indicator Under Scrutiny

The one bright spot is coach productivity. Active earning coach productivity grew for the third consecutive quarter, up 41% year-over-year and 20% sequentially. “We now have a clear trend of increasing coach productivity both year-over-year and sequentially.” — James Maloney, Chief Financial Officer · 2026-08-03 Revenue per active earning coach hit its highest level since Q2 2022. Management views this as the leading indicator for future coach growth, echoing prior commentary: “We are not going to predict exactly which quarter, but based on history, we believe that is going to happen in a short period of time.” — James P. Maloney, Chief Financial Officer · 2026-05-04 The challenge is that the absolute coach count is still falling, and GLP-1 medication adoption continues to disrupt the traditional weight loss category. The strategic response includes a revamped compensation plan focused on developing Executive Directors, and a new coach training platform. The company's Catalyst program—launched in Q2—aims to drive cost savings through facility rationalization and AI efficiencies, with the goal of returning to profitability by Q4 2026. CFO Jim Maloney provided guidance: Q3 revenue of $60–80 million and a loss per share of $0.15–0.65, with full-year revenues of $270–300 million. “We continue to include in our guidance the belief that improvements to get back to profitability will start in Q4 2026.” — James Maloney, Chief Financial Officer · 2026-08-03

A Coin with Two Sides

The market appears cautiously optimistic. MED's stock is up 18.8% over the last 90 days, recovering from a long-term collapse that saw shares fall 96.4% from their 2021 peak. The recent uptrend suggests investors are buying into the trilogy of new brand, metabolic health focus, and cost discipline. Yet the fundamental picture remains stark: revenue is a sixth of its former peak, and the coach base is still shrinking. The company's own history shows that coach productivity gains typically precede coach growth by 6–9 months, but the GLP-1 environment introduces uncertainty. Johnson's closing remarks captured the mood:

We are energized by the positive momentum in coach productivity and engagement, and are confident that the foundational work we are doing today centering on speed, simplicity, scale, and stewardship is setting the stage for a return to profitability in the fourth quarter.
Nicholas Johnson, Chief Executive Officer · 2026-08-03

With a strong balance sheet and a clear cost-cutting blueprint, Medifast has the financial resilience to execute its 10-year roadmap. The question is whether Trilivy and the metabolic health narrative can reverse the coach exodus—and whether the productivity surge is sustainable enough to turn the tide. Prior calls have leaned heavily on the same levers: “We have a complete offer that allows us to use LifeMD where necessary.” — Dan Chard, Chairman and Chief Executive Officer · 2025-04-28 That partnership, now largely amortized, was an earlier attempt to address GLP-1 users. Today, the focus is on owning the metabolic health category. The Trilivy launch and the renewed emphasis on productivity gains are bets that the coach-led model can thrive in a post-GLP-1 world. Time will tell if these new consumer brand initiatives translate into growth—or simply buy time for a company fighting to remain relevant.